Predictors of nonrelapse mortality among patients with grade II-IV acute GVHD
| Predictor . | No. of patients . | Univariate . | Multivariate . | ||||
|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | ||
| Patient age | |||||||
| Older than 40 y | 171 | 0.9 | 0.7-1.3 | .7 | — | — | — |
| 40 y or younger | 94 | 1.0 | Reference | — | — | — | — |
| Patient sex | |||||||
| Female | 101 | 1.2 | 0.8-1.7 | .3 | — | — | — |
| Male | 164 | 1.0 | Reference | — | — | — | — |
| Donor/patient sex* | |||||||
| Female/male | 73 | 1.3 | 0.96-1.9 | .09 | — | — | — |
| Other | 190 | 1.0 | Reference | — | — | — | — |
| Acute GVHD | |||||||
| Hyperacute | 73 | 1.1 | 0.8-1.6 | .6 | — | — | — |
| Other | 192 | 1.0 | Reference | — | — | — | — |
| Donor type | |||||||
| Mrel | 137 | 1.0 | Reference | — | — | — | — |
| MUD | 97 | 1.4 | 0.98-2.1 | .06 | — | — | — |
| MMrel | 31 | 1.7 | 1.03-2.9 | .04 | — | — | — |
| Donor type/hyperacute GVHD | |||||||
| Mrel and no hyperacute | 109 | 1.0 | Reference | — | — | — | — |
| Mrel and hyperacute | 28 | 0.6 | 0.3-1.2 | .1 | — | — | — |
| MUD/MMrel and no hyperacute | 83 | 1.2 | 0.8-1.8 | .4 | — | — | — |
| MUD/MMrel and hyperacute | 45 | 1.7 | 1.1-2.7 | .02 | — | — | — |
| MUD/MMrel and hyperacute vs all other | 45 | 1.7 | 1.1-2.6 | .01 | 1.4 | 0.9-2.1 | .15 |
| Response to first-Line therapy | |||||||
| CR/PR | 116 | 1.0 | Reference | — | 1.0 | Reference | — |
| Other | 143 | 2.1 | 1.4-2.9 | < .001 | 1.96 | 1.3-2.8 | < .001 |
| Conditioning regimen | |||||||
| Reduced Intensity | 88 | 1.0 | Reference | — | 1.0 | Reference | — |
| HDC | 139 | 0.8 | 0.7-1.2 | .4 | 1.0 | Reference | — |
| TBI | 38 | 1.6 | 0.98-2.7 | .06 | 1.7 | 1.1-2.7 | .02 |
| No. of prior chemotherapy lines* | |||||||
| More than 5 | 21 | 0.8 | 0.4-1.7 | .6 | — | — | — |
| 5 or fewer | 243 | 1.0 | Reference | — | — | — | — |
| Prior autologous transplant | |||||||
| Yes | 17 | 0.6 | 0.2-1.4 | .2 | — | — | — |
| No | 248 | 1.0 | Reference | — | — | — | — |
| Diagnosis | |||||||
| Lymphoid | 95 | 1.1 | 0.7-1.5 | .8 | — | — | — |
| Myeloid | 143 | 1.0 | Reference | — | — | — | — |
| Multiple myeloma | 11 | 0.6 | 0.2-1.7 | .4 | — | — | — |
| Solid tumor/other | 16 | 0.45 | 0.2-1.2 | .12 | — | — | — |
| Disease status at transplantation | |||||||
| Not in remission | 181 | 1.2 | 0.8-1.7 | .4 | — | — | — |
| Remission | 84 | 1.0 | Reference | — | — | — | — |
| Cell source among Mrel | |||||||
| PB | 118 | 1.5 | 0.7-3.2 | .3 | — | — | — |
| BM | 19 | 1.0 | Reference | — | — | — | — |
| Predictor . | No. of patients . | Univariate . | Multivariate . | ||||
|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | ||
| Patient age | |||||||
| Older than 40 y | 171 | 0.9 | 0.7-1.3 | .7 | — | — | — |
| 40 y or younger | 94 | 1.0 | Reference | — | — | — | — |
| Patient sex | |||||||
| Female | 101 | 1.2 | 0.8-1.7 | .3 | — | — | — |
| Male | 164 | 1.0 | Reference | — | — | — | — |
| Donor/patient sex* | |||||||
| Female/male | 73 | 1.3 | 0.96-1.9 | .09 | — | — | — |
| Other | 190 | 1.0 | Reference | — | — | — | — |
| Acute GVHD | |||||||
| Hyperacute | 73 | 1.1 | 0.8-1.6 | .6 | — | — | — |
| Other | 192 | 1.0 | Reference | — | — | — | — |
| Donor type | |||||||
| Mrel | 137 | 1.0 | Reference | — | — | — | — |
| MUD | 97 | 1.4 | 0.98-2.1 | .06 | — | — | — |
| MMrel | 31 | 1.7 | 1.03-2.9 | .04 | — | — | — |
| Donor type/hyperacute GVHD | |||||||
| Mrel and no hyperacute | 109 | 1.0 | Reference | — | — | — | — |
| Mrel and hyperacute | 28 | 0.6 | 0.3-1.2 | .1 | — | — | — |
| MUD/MMrel and no hyperacute | 83 | 1.2 | 0.8-1.8 | .4 | — | — | — |
| MUD/MMrel and hyperacute | 45 | 1.7 | 1.1-2.7 | .02 | — | — | — |
| MUD/MMrel and hyperacute vs all other | 45 | 1.7 | 1.1-2.6 | .01 | 1.4 | 0.9-2.1 | .15 |
| Response to first-Line therapy | |||||||
| CR/PR | 116 | 1.0 | Reference | — | 1.0 | Reference | — |
| Other | 143 | 2.1 | 1.4-2.9 | < .001 | 1.96 | 1.3-2.8 | < .001 |
| Conditioning regimen | |||||||
| Reduced Intensity | 88 | 1.0 | Reference | — | 1.0 | Reference | — |
| HDC | 139 | 0.8 | 0.7-1.2 | .4 | 1.0 | Reference | — |
| TBI | 38 | 1.6 | 0.98-2.7 | .06 | 1.7 | 1.1-2.7 | .02 |
| No. of prior chemotherapy lines* | |||||||
| More than 5 | 21 | 0.8 | 0.4-1.7 | .6 | — | — | — |
| 5 or fewer | 243 | 1.0 | Reference | — | — | — | — |
| Prior autologous transplant | |||||||
| Yes | 17 | 0.6 | 0.2-1.4 | .2 | — | — | — |
| No | 248 | 1.0 | Reference | — | — | — | — |
| Diagnosis | |||||||
| Lymphoid | 95 | 1.1 | 0.7-1.5 | .8 | — | — | — |
| Myeloid | 143 | 1.0 | Reference | — | — | — | — |
| Multiple myeloma | 11 | 0.6 | 0.2-1.7 | .4 | — | — | — |
| Solid tumor/other | 16 | 0.45 | 0.2-1.2 | .12 | — | — | — |
| Disease status at transplantation | |||||||
| Not in remission | 181 | 1.2 | 0.8-1.7 | .4 | — | — | — |
| Remission | 84 | 1.0 | Reference | — | — | — | — |
| Cell source among Mrel | |||||||
| PB | 118 | 1.5 | 0.7-3.2 | .3 | — | — | — |
| BM | 19 | 1.0 | Reference | — | — | — | — |
Total number of patients is 265.
Total number of patients differs slightly because of unknown values.